FDA Alerts Providers to Recall of Compounded Drug Products
Coastal Meds LLC, which compounds drugs as an outsourcing facility, has voluntarily recalled all of its products marketed as sterile due to visible particles in some of the drug vials for injection, the Food and Drug Administration announced Friday. Health care providers should immediately quarantine and not administer any Coastal Meds sterile drug products intended for injection, FDA said. The agency encourages health care professionals and patients to report any adverse reactions or quality problems to the MedWatch program.
Related News Articles
Headline
The Department of Labor has issued a proposed rule to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to disclose…
Headline
The Department of Health and Human Services Office of Inspector General Jan. 27 released a bulletin addressing how direct-to-consumer drug programs can sell…
Headline
The Centers for Medicare & Medicaid Services Jan. 27 announced 15 drugs under Medicare Parts D and B selected for the third round of price negotiations.…
Headline
The White House released a health care plan Jan. 15 addressing drug prices, health insurance premiums and price transparency efforts. The plan includes…
Headline
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver…
Headline
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model for Medicare Part D and Medicaid beneficiaries. The Better…